Blood and Urine Collection in Glioblastoma Radiation Therapy
Part of Cancer clinical trials.
This study collects blood and urine samples from patients receiving radiation treatment for glioblastoma (a serious brain tumor) to help researchers understand how the body responds to radiation therapy. Participating is straightforward—you provide samples during your regular treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of glioblastoma multiforme (a type of brain tumor) in the upper brain
- Good enough overall health to tolerate radiation therapy (Karnofsky score above 60)
- Planning to receive radiation therapy as part of your treatment
- Able to understand the study and sign consent, or have a legal representative do so
- No other active cancers (except non-melanoma skin cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This study aims to improve understanding of glioblastoma (and gliosarcoma) by preserving live, usable brain-tissue samples during brain surgery. If you’re having repeat tumor surgery or your scans suggest these cancers, the study may ask to collect tissue for research.
This study tests how best to measure and track glioblastoma treatment while using MRI (a body scanner) to guide radiation. It may help improve how doctors assess the radiation response during therapy.
This trial tests whether using your own blood stem cells to support high-dose chemotherapy can help treat newly diagnosed glioblastoma, an aggressive brain cancer. It aims to improve outcomes for patients whose tumors have a specific genetic marker (unmethylated MGMT) and who have had surgery.
This study uses special MRI imaging with deuterium to see how radiotherapy affects newly diagnosed glioblastoma (GBM) with an IDH-wildtype tumor. It may help doctors better understand treatment response and timing, potentially improving how radiotherapy is planned.
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.